PCOS Is Now PMOS: Why Experts Are Rethinking Women’s Metabolic and Longevity Health

For decades, millions of women were handed a diagnosis that was, at its core, a misnomer. Polycystic ovary syndrome, PCOS, is named the ovaries as the primary site of dysfunction despite overwhelming evidence that the condition extends far beyond them. It implied cysts where there were often none. It framed a profoundly systemic, metabolic disorder as a largely gynaecological inconvenience. That framing had consequences, and they were not trivial. 

On 13 May 2025, a landmark global consensus study published in The Lancet formally closed that chapter. PCOS has been officially renamed polyendocrine metabolic ovarian syndrome (PMOS) following one of the most expansive renaming processes in modern medicine, involving 56 leading academic, clinical, and patient organisations, more than 14,000 survey responses from people living with the condition, and over 14 years of collaborative research led by Professor Helena Teede at Monash University.

The shift from PCOS to PMOS is not a cosmetic update. It is a scientific correction, and for anyone who follows the science of women's metabolic health and longevity, it is long overdue. 

Why Was PCOS Renamed PMOS? 

The original terminology had a fundamental problem: it was anchored to a feature that was neither universal nor defining. The term "polycystic ovary syndrome" suggested that pathological ovarian cysts were at the heart of the condition, yet many women diagnosed with PCOS never presented with identifiable cysts at all. What appear on ultrasound as "cysts" are, in most cases, immature follicles reflecting hormonal disruption rather than structural ovarian pathology. The name, in short, was describing a secondary finding whilst obscuring the primary mechanism. 

As Professor Teede noted in commentary surrounding the consensus publication, it was "very clear that the name was inaccurate," causing confusion for both patients and clinicians and contributing to delayed diagnosis and fragmented care.

The new name, polyendocrine metabolic ovarian syndrome, immediately conveys something more accurate and useful: that this is a condition involving multiple endocrine axes, metabolic dysregulation, and ovarian involvement, with none of these three dimensions sufficient on its own to define it. 

The Lancet paper outlined a rigorous, multistep global consensus process using iterative surveys, modified Delphi methods, and nominal group technique workshops. Implementation of the new terminology is expected to roll out over three years, with full integration into international disease classification systems anticipated by 2028. 

PCOS vs PMOS: How the Framing Changed

Why the Old PCOS Label Failed Many Women 

The damage done by imprecise medical terminology is rarely dramatic. It accumulates quietly, in consulting rooms, in delayed referrals, in symptoms dismissed as anxiety or weight management issues. For women with what is now called PMOS, this accumulation was substantial. 

Because the old framing centred on reproductive function, fatigue, weight gain, mood disturbance, insulin dysregulation, and persistent low-grade inflammation were frequently minimised or attributed to other causes. Women presenting without the "classic" picture of irregular cycles and visible ovarian changes were often told their hormones were normal. Clinicians trained to look for ovarian cysts naturally did so, and when they were absent, the diagnostic trail went cold. Meanwhile, the metabolic dysfunction progressed. 

This fertility-first framing also shaped where research funding flowed and how treatment was framed. Women were often told the condition mattered primarily in the context of wanting to conceive. The broader implications for cardiovascular risk, type 2 diabetes, and long-term metabolic health received comparatively little attention in clinical consultations. 

There is something worth acknowledging in this history: it reflects a wider pattern in medicine in which women's systemic health has historically been interpreted through a reproductive lens. Correcting the terminology is therefore not merely an academic exercise. It is an act of clinical equity. 

PMOS Is Not Just a Hormonal Disorder. It Is a Metabolic Longevity Issue. 

This is where the science becomes genuinely significant, and where the implications extend beyond diagnosis and into the territory of longevity medicine. 

Fig: The PMOS Metabolic Web

At the cellular level, PMOS is characterised by a cluster of interconnected dysfunctions that align almost precisely with the mechanisms that accelerate biological ageing. Insulin resistance is perhaps the most well-documented feature, present in the majority of women with the condition, regardless of body weight. Chronically elevated insulin drives compensatory hyperinsulinaemia, amplifies androgen production, impairs ovarian function, and sets in motion a cascade of downstream metabolic consequences. Crucially, insulin resistance is also one of the most potent known drivers of accelerated biological ageing, increasing the risk of type 2 diabetes, cardiovascular disease, non-alcoholic fatty liver disease, and cognitive decline. 

More recently, researchers have turned their attention to mitochondrial dysfunction as a key pathological feature of PMOS. A 2025 review published in the International Journal of Molecular Sciences confirmed that androgen excess and insulin resistance collectively enhance oxidative stress, which subsequently impairs mitochondrial function, depletes ATP, and disrupts mitochondrial biogenesis. Mitochondria are not merely the cell's energy generators; they are central regulators of cellular ageing, apoptosis, and metabolic flexibility. 

Compounding this is chronic low-grade inflammation. Women with PMOS exhibit elevated circulating levels of pro-inflammatory cytokines, including tumour necrosis factor-alpha and interleukin-6, reflecting a state of persistent systemic inflammation that sits beneath the threshold of acute illness but above the baseline of optimal health. This inflammatory phenotype is increasingly recognised as a central driver of biological ageing, cardiovascular disease, and neurodegeneration. 

The cardiovascular data are worth taking seriously. A UK study examining 175,000 women with PCOS found significantly elevated rates of myocardial infarction, angina, and revascularisation procedures in young women with the condition. These are not remote statistical risks. They represent meaningful shifts in long-term health trajectory, driven not by ovarian morphology but by the very metabolic mechanisms that the new PMOS classification finally acknowledges. 

Why Functional Medicine Doctors Saw This Shift Earlier 

The reframing now formalised in The Lancet is one that practitioners of functional and integrative medicine had been advocating for some time. This is not a criticism of conventional medicine, which moves necessarily by consensus and evidence accumulation, but an observation that root-cause approaches to chronic disease had already placed metabolic dysfunction, gut integrity, cortisol dysregulation, and inflammatory burden at the centre of PCOS management long before the renaming arrived. 

Functional medicine's emphasis on identifying upstream drivers rather than managing downstream symptoms positioned PCOS as a disorder of systems biology from early on. Practitioners in this space were already testing fasting insulin, HOMA-IR, and high-sensitivity CRP in women with irregular cycles and fatigue, connecting the dots between stress physiology, adrenal function, sleep disruption, and hormonal dysregulation. 

The tools, frameworks, and therapeutic interventions developed within systems-based medicine, including dietary modification for insulin sensitivity, targeted supplementation for mitochondrial support, microbiome-focused interventions, and stress pathway modulation, now have a more solid institutional foundation. The languages of conventional and functional medicine are converging around a shared metabolic framework, and that convergence benefits patients. 

The Gut Microbiome, Inflammation, and PMOS 

One of the more illuminating developments in PMOS research has been the growing body of evidence linking gut microbiome dysbiosis to the condition's core features. Multiple studies have confirmed that women with PMOS exhibit characteristic patterns of reduced microbial diversity, imbalances in the ratio of Firmicutes to Bacteroidetes, and altered microbial metabolite production that directly influence insulin signalling, androgen metabolism, and systemic inflammation. 

The mechanism is increasingly well understood. Dysbiosis compromises the integrity of the intestinal barrier, allowing lipopolysaccharide, a component of gram-negative bacterial cell walls, to enter the systemic circulation. This bacterial endotoxaemia triggers a persistent low-grade inflammatory response, further worsening insulin resistance and amplifying the hormonal dysfunction central to PMOS. Research published in eClinicalMedicine and Frontiers in Microbiology has underscored the bidirectional relationship between gut health and PMOS: metabolic dysfunction alters the microbiome, and microbiome dysbiosis deepens metabolic dysfunction. 

The gut-brain axis adds a further dimension. Short-chain fatty acids, produced by beneficial gut bacteria through fermentation of dietary fibre, play a significant regulatory role in appetite, mood, and systemic metabolism. When the microbiome is compromised, the effects are not confined to digestion. They ripple outward into every metabolic system. 

What Women Should Track Beyond Hormones 

If PMOS is fundamentally a metabolic and systemic condition, then monitoring it requires a metabolic and systemic assessment, not simply a hormone panel. Women who want a meaningful picture of their PMOS trajectory should be investigating the following: 

• Fasting insulin and HOMA-IR are considerably more sensitive early indicators of metabolic dysfunction than fasting glucose or HbA1c alone. Insulin resistance often precedes any change in blood glucose by years, making fasting insulin an essential early-warning marker that remains routinely underutilised in primary care. 
• HbA1c provides a three-month average of blood glucose regulation, but should be interpreted alongside fasting insulin rather than in isolation. A "normal" HbA1c in the context of elevated fasting insulin still represents significant underlying metabolic strain. 
• High-sensitivity CRP quantifies systemic inflammatory burden and should be part of any PMOS monitoring panel. Levels above 1 mg/L, particularly when persistent, indicate clinically meaningful inflammatory activity. 
• Fasting triglycerides reflect metabolic flexibility and hepatic insulin sensitivity. Elevated triglycerides, even within nominally "normal" ranges, are often the first lipid abnormality to emerge in insulin resistance. 
• Body composition rather than BMI provides a more meaningful picture of metabolic health. Visceral adiposity, even in women with normal BMI, is an independent driver of insulin resistance and inflammatory load. 
• Sleep quality warrants serious clinical attention in PMOS. Obstructive sleep apnoea is significantly more prevalent in women with the condition and independently worsens insulin sensitivity and inflammatory markers. 
• Microbiome health, assessed through comprehensive stool analysis, is increasingly accessible and clinically informative. Markers of microbial diversity, inflammatory microbial metabolites, and intestinal permeability can guide targeted therapeutic interventions. 

Why PMOS May Redefine Women's Preventive Healthcare 

The renaming of PCOS to PMOS arrives at a moment when medicine is undergoing a broader philosophical reorientation, from symptom management toward systems biology, from reactive intervention toward genuine prevention. PMOS sits precisely at this intersection, and its reclassification as a polyendocrine metabolic condition rather than a reproductive syndrome has the potential to accelerate that reorientation in women's health specifically. 

For too long, the dominant paradigm in women's health framed the body's metabolic processes as secondary to reproductive ones. Fertility was the narrative through which women's hormonal health was understood, funded, and researched. PMOS challenges that framing at its foundation. It demands that insulin resistance, mitochondrial function, inflammatory biology, and cardiovascular risk be considered primary concerns in women's health, not afterthoughts appended to conversations about cycles and conception. 

The implications for preventive medicine are substantial. If PMOS is understood as an early indicator of metabolic ageing, then identifying and addressing it in the second or third decade of life creates a meaningful opportunity to alter long-term health trajectories. The tools of longevity medicine, metabolic monitoring, lifestyle modification, targeted nutrition, microbiome support, and inflammation management are precisely the tools most relevant to PMOS management. The two disciplines are not parallel. They are, in many respects, addressing the same underlying biology. 

What this renaming signals, ultimately, is that the medical community is finally prepared to see women's metabolic health in its full complexity. For the 170 million people affected by this condition worldwide, the reclassification of PMOS as a multisystem metabolic disorder represents a form of scientific vindication. And for the clinicians, researchers, and practitioners who follow the science of longevity and chronic disease prevention, it represents one of the most significant shifts in women's health in recent memory. 

The name has changed. What follows from that change may matter even more.

Frequently Asked Questions

1. What is PMOS, and how is it different from PCOS?
   PMOS, polyendocrine metabolic ovarian syndrome, is the newly official name for the condition previously known as PCOS. The renaming reflects a shift in medical understanding: PMOS is now recognised as a complex, multisystem condition involving endocrine, metabolic, ovarian, dermatological, and psychological health, rather than primarily a gynaecological disorder defined by ovarian cysts.
2. Why was PCOS renamed PMOS?
   PCOS was renamed because the original term was medically inaccurate. Many women diagnosed with PCOS did not present with ovarian cysts, and the name obscured the condition's true nature as a metabolic and hormonal syndrome. The global consensus process, published in The Lancet in May 2025, was led by Monash University and involved 56 organisations and over 14,000 patient responses.
3. Does the PMOS rename affect my existing diagnosis?
   No. Patients previously diagnosed with PCOS are now considered to have PMOS. The clinical criteria and diagnostic process remain the same; only the name and its formal framing have changed. The new terminology will be phased into clinical guidelines and disease classification systems over the next three years.
4. What metabolic risks are associated with PMOS?
   PMOS is associated with insulin resistance, elevated cardiovascular risk, type 2 diabetes, mitochondrial dysfunction, and chronic low-grade inflammation. These mechanisms overlap significantly with drivers of accelerated biological ageing, making early metabolic monitoring and lifestyle intervention important for women with the condition.
5. What biomarkers should women with PMOS track?
   Beyond the standard hormone panel, women with PMOS should consider tracking fasting insulin, HOMA-IR, HbA1c, high-sensitivity CRP, fasting triglycerides, body composition, sleep quality, and microbiome health. These markers provide a more complete picture of metabolic health and disease trajectory than reproductive hormones alone.